HGS, BioInvent ink antibody deal

Human Genome Sciences and BioInvent International have inked a deal to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS. BioInvent will use its antibody discovery technology to generate and develop monoclonal antibody candidates, with a focus on the field of inflammation. Financial terms were not disclosed. Release

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.